Perrigo Company plc Goodwill, Acquired During Period
Perrigo Company plc (PRGO) reported Goodwill, Acquired During Period of $559.50 million for the 12-month period ending 2022-12-31, per its 10-K filed 2024-02-27.
Discontinued › Notes › Intangible Assets › Goodwill and Other
us-gaap:GoodwillAcquiredDuringPeriod · last filed 2024-02-27
- Perrigo Company plc goodwill, acquired during period for the quarter ending 2022-12-31 was -$58.60M.
- Perrigo Company plc goodwill, acquired during period for the quarter ending 2022-10-01 was $1.90M.
- Perrigo Company plc goodwill, acquired during period for the quarter ending 2020-12-31 was $6.20M.
- Perrigo Company plc goodwill, acquired during period for the quarter ending 2020-09-26 was -$400.00K.
- Perrigo Company plc goodwill, acquired during period for fiscal 2022 was $559.50M.
- Perrigo Company plc goodwill, acquired during period for fiscal 2020 was $22.10M, a 92.41% decline from fiscal 2019.
- Perrigo Company plc goodwill, acquired during period for fiscal 2019 was $291.10M.
- Perrigo Company plc goodwill, acquired during period for fiscal 2016 was $1.70M.
| Period end | Goodwill, Acquired During Period 3 month | Goodwill, Acquired During Period 6 month | Goodwill, Acquired During Period 9 month | Goodwill, Acquired During Period 9 month as first filed | Goodwill, Acquired During Period 12 month | Goodwill, Acquired During Period 12 month as first filed |
|---|---|---|---|---|---|---|
| 2022-12-31 | -$58.60M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$56.70M derived: sum of 2 quarters · filed 2024-02-27 | $559.50M 10-K · filed 2024-02-27 | |||
| 2022-10-01 | $1.90M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $618.10M 10-Q · filed 2022-11-08 | ||||
| 2022-07-02 | $616.20M 10-Q · filed 2022-08-09 | |||||
| 2020-12-31 | $6.20M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-01 | $5.80M derived: sum of 2 quarters · filed 2022-03-01 | $22.10M 10-K · filed 2022-03-01 | |||
| 2020-09-26 | -$400.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | $15.90M 10-Q · filed 2020-11-05 | ||||
| 2020-06-27 | $16.30M 10-Q · filed 2020-08-05 | |||||
| 2019-12-31 | -$36.30M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-01 | $291.10M 10-K · filed 2021-03-01 | ||||
| 2019-09-28 | $327.40M 10-Q · filed 2019-11-06 | |||||
| 2016-12-31 | -$100.00K derived: 10-K 12 month − 10-Q/A 9 month · filed 2018-03-01 | $0.00 derived: sum of 2 quarters · filed 2018-03-01 | -$500.00K derived: sum of 3 quarters · filed 2018-03-01 | $1.70M 10-K · filed 2018-03-01 | ||
| 2016-10-01 | $100.00K derived: 10-Q/A 9 month − 10-Q/A 6 month · filed 2017-05-23 | -$400.00K derived: sum of 2 quarters · filed 2017-05-23 | $1.80M 10-Q/A · filed 2017-05-23 | $1.90M 10-Q · filed 2016-11-10 | -$18.20M derived: sum of 4 quarters · filed 2018-03-01 | |
| 2016-07-02 | -$500.00K derived: 10-Q/A 6 month − 10-Q/A 3 month · filed 2017-05-22 | $1.70M 10-Q/A · filed 2017-05-22 | -$18.30M derived: sum of 3 quarters · filed 2018-03-01 | $98.80M derived: sum of 4 quarters · filed 2018-03-01 | ||
| 2016-04-02 | $2.20M 10-Q/A · filed 2017-05-22 | -$17.80M derived: sum of 2 quarters · filed 2018-03-01 | $99.30M derived: sum of 3 quarters · filed 2018-03-01 | |||
| 2015-12-31 | -$20.00M derived: 10-K 6 month − 10-Q 3 month · filed 2018-03-01 | $97.10M 10-K · filed 2018-03-01 | ||||
| 2015-09-26 | $117.10M 10-Q · filed 2015-11-02 | |||||
| 2015-06-27 | $1.27B 10-K · filed 2017-05-22 | $1.52B 10-K · filed 2015-08-13 | ||||
| 2014-12-27 | $900.00K derived: 10-Q 6 month − 8-K 3 month · filed 2015-02-05 | $900.00K 10-Q · filed 2015-02-05 | $257.80M derived: sum of 3 quarters · filed 2016-02-25 | $274.30M derived: sum of 4 quarters · filed 2016-02-25 | ||
| 2014-09-27 | $0.00 8-K · filed 2014-11-20 | $256.90M derived: sum of 2 quarters · filed 2016-02-25 | $273.40M derived: sum of 3 quarters · filed 2016-02-25 | |||
| 2014-06-28 | $256.90M derived: 10-KT 12 month − 10-Q 9 month · filed 2016-02-25 | $273.40M derived: sum of 2 quarters · filed 2016-02-25 | $2.35B 10-KT · filed 2016-02-25 | |||
| 2014-03-29 | $16.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-05-07 | $2.09B 10-Q · filed 2014-05-07 | ||||
| 2013-12-28 | $2.08B 10-Q · filed 2014-02-06 | |||||
| 2013-06-29 | $308.60M 10-K · filed 2014-08-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |